| scholarly article | Q13442814 |
| P50 | author | Frederik B. Clausen | Q42327851 |
| P2093 | author name string | Frederik Banch Clausen | |
| P2860 | cites work | Prenatal Diagnosis of Fetal RhD Status by Molecular Analysis of Maternal Plasma | Q28314918 |
| Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality | Q28732243 | ||
| Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield | Q28744238 | ||
| Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry | Q33317800 | ||
| RhD haemolytic disease of the fetus and the newborn | Q33901403 | ||
| Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women | Q33917070 | ||
| Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis | Q34028063 | ||
| Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience | Q34192088 | ||
| From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges | Q34286705 | ||
| Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008 | Q34306068 | ||
| Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. | Q34385131 | ||
| Evaluation of a novel assay for detection of the fetal marker RASSF1A: facilitating improved diagnostic reliability of noninvasive prenatal diagnosis | Q34425220 | ||
| A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales | Q34556245 | ||
| Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma | Q34706395 | ||
| Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women | Q34853996 | ||
| Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program | Q34936608 | ||
| Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma | Q34988198 | ||
| Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications | Q35023094 | ||
| Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD | Q35034936 | ||
| Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed | Q35043252 | ||
| Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma | Q35069908 | ||
| Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis | Q35290338 | ||
| A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant | Q35870526 | ||
| Non-invasive antenatal RHD typing | Q36431820 | ||
| Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study | Q36538133 | ||
| Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma | Q36794228 | ||
| Fetal anemia due to non-Rhesus-D red-cell alloimmunization | Q37132178 | ||
| Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects | Q37351817 | ||
| The SAFE project: towards non-invasive prenatal diagnosis | Q37416234 | ||
| The controversy about controls for fetal blood group genotyping by cell-free fetal DNA in maternal plasma | Q37934379 | ||
| Uses of cell free fetal DNA in maternal circulation | Q38006298 | ||
| Variants of RhD--current testing and clinical consequences | Q38083742 | ||
| Cell-free fetal DNA and maternal serum analytes for monitoring embryonic and fetal status | Q38090127 | ||
| Circulating cell free DNA: Preanalytical considerations | Q38111116 | ||
| Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers | Q38459998 | ||
| Noninvasive fetal blood grouping: present and future | Q39868111 | ||
| Reliable test for prenatal prediction of fetal RhD type using maternal plasma from RhD negative women. | Q40380350 | ||
| Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service | Q40626763 | ||
| Feasibility of fetal-derived hypermethylated RASSF1A sequence quantification in maternal plasma--next step toward reliable non-invasive prenatal diagnostics | Q42877106 | ||
| Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. | Q43787267 | ||
| Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3+1G>A) allele | Q43851609 | ||
| Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities | Q44329157 | ||
| Next-generation sequencing: proof of concept for antenatal prediction of the fetal Kell blood group phenotype from cell-free fetal DNA in maternal plasma | Q44639381 | ||
| Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis | Q44886205 | ||
| RHD and RHCE variant and zygosity genotyping via multiplex ligation-dependent probe amplification | Q45026016 | ||
| Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions. | Q45185754 | ||
| Evaluation of single-nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups. | Q45984957 | ||
| Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis | Q46172895 | ||
| RHD gene polymorphisms in alloimmunized RhD-negative individuals with high rate of racial admixture. | Q46195691 | ||
| One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy | Q47683487 | ||
| Noninvasive fetal RHD genotyping from maternal plasma. Use of a new developed Free DNA Fetal Kit RhD. | Q47808590 | ||
| The analysis of nucleotide substitutions, gaps, and recombination events between RHD and RHCE genes through complete sequencing | Q47840459 | ||
| Report of the fourth International Workshop on molecular blood group genotyping. | Q50526732 | ||
| Study of compliance with a new, targeted antenatal D immunization prevention programme in Denmark. | Q50556010 | ||
| Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. | Q50792929 | ||
| Postnatal outcome in neonates with severe Rhesus c compared to rhesus D hemolytic disease. | Q50899924 | ||
| Early non-invasive detection of fetal Y chromosome sequences in maternal plasma using multiplex PCR. | Q51366817 | ||
| Noninvasive prenatal RHD genotyping by real-time polymerase chain reaction using plasma from D-negative pregnant women. | Q51958913 | ||
| Multiplexed analysis of circulating cell-free fetal nucleic acids for noninvasive prenatal diagnostic RHD testing. | Q53288194 | ||
| Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood--a meta-analysis. | Q53597278 | ||
| Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. | Q54301772 | ||
| Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. | Q54342228 | ||
| Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. | Q54393922 | ||
| Incorporation of fetal DNA detection assay in a noninvasive RhD diagnostic test. | Q54414971 | ||
| Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. | Q54440345 | ||
| The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. | Q54520641 | ||
| Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c. | Q54539332 | ||
| Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. | Q54566658 | ||
| Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. | Q54574187 | ||
| Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. | Q54646324 | ||
| Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies. | Q54677055 | ||
| Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. | Q54688617 | ||
| Workshop report on the extraction of foetal DNA from maternal plasma | Q56001878 | ||
| Non-invasive fetal RHD genotyping in the first trimester of pregnancy | Q56001887 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 409-415 | |
| P577 | publication date | 2014-02-05 | |
| P1433 | published in | Prenatal Diagnosis | Q15760059 |
| P1476 | title | Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care | |
| P478 | volume | 34 |
| Q36695389 | An easy test but a hard decision: ethical issues concerning non-invasive prenatal testing for autosomal recessive disorders |
| Q42393162 | Cell-free fetal DNA: the new tool in fetal medicine |
| Q43448023 | Costs and benefits of non-invasive fetal RhD determination |
| Q50246909 | Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran |
| Q39084118 | First trimester noninvasive fetal RHD genotyping using maternal dried blood spots |
| Q37342219 | Global perspectives on clinical adoption of NIPT |
| Q26999426 | Non-invasive prenatal testing: a review of international implementation and challenges |
| Q30667824 | Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments |
| Q54088983 | Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis. |
| Q35245269 | The amniotic fluid transcriptome as a guide to understanding fetal disease |
Search more.